KKR has bought all shares in Bushu Pharmaceuticals, a pure-play pharmaceutical contract development and manufacturing organization (CDMO) based in Japan, from BPEA EQT.

Bushu Pharma is focused on producing, processing and delivering healthcare products to patients spanning categories including pharmaceuticals and clinical trial materials. KKR aims to drive Bushu Pharma’s growth and further the company’s position as a CDMO for the pharmaceuticals market in Japan and globally. At close, KKR looks to work with Bushu Pharma’s management team to expand into new and growing segments, such as injectibles, invest in capacity expansion and quality control and explore organic and inorganic growth opportunities.

“By leveraging KKR’s deep experience in healthcare, tech, and supply chain solutions, we aim to help Bushu Pharma to further scale its best-in-class business and to drive growth and technical innovation that will ultimately benefit patients in Japan and around the world,” says Hiro Hirano, co-head of private equity for KKR Asia Pacific and chief executive officer of KKR Japan.